Theravectys

Developer of vaccines to treat infectious diseases and cancer caused by HTLV-1 infection

placeParis, Ile De France, France calendar_todayFounded 2005 groups19 employees language theravectys.com

Registered entities

Innovation

26 patent families (9 granted) — focus: Chemistry & metallurgy, Human necessities, Emerging technologies, Physics & computing; filing pace steady. Cited 2,108 times.

YearFilings
20158
201612
20177
20184
20195
20205
20212
20229
20237
20248
20256
20261

Investor mix

8 investors on record; lead investors include FGP Capital, iXLife Capital.

Investor typeCountShare
Venture capital113%
Bank & private debt113%
Other / undisclosed675%
Coming soon